bluebird bio, Inc. (BLUE) Insider Trading Activity
NASDAQ$3.31
Market Cap
$32.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
471 of 878
Rank in Industry
275 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BLUE Insider Trading Activity
BLUE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $37,206 | 14 | 100 |
Related Transactions
| Vittiglio Joseph | Chief Business & Legal Officer | 0 | $0 | 1 | $1,759 | $-1,759 |
| Colvin Richard A | Chief Medical Officer | 0 | $0 | 4 | $4,116 | $-4,116 |
| Klima Thomas J | See Remarks | 0 | $0 | 4 | $7,117 | $-7,117 |
| Obenshain Andrew | President and CEO | 0 | $0 | 5 | $24,214 | $-24,214 |
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Activity of bluebird bio, Inc.
Over the last 12 months, insiders at bluebird bio, Inc. have bought $0 and sold $37,206 worth of bluebird bio, Inc. stock.
On average, over the past 5 years, insiders at bluebird bio, Inc. have bought $0 and sold $475,886 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,364 shares for transaction amount of $1M was made by Leschly Nick (President and CEO) on 2015‑12‑08.
List of Insider Buy and Sell Transactions, bluebird bio, Inc.
| 2025-03-03 | Sale | Obenshain Andrew | President and CEO | 921 0.0095% | $3.92 | $3,610 | +3.09% | |
| 2025-03-03 | Sale | Klima Thomas J | See Remarks | 500 0.0051% | $3.92 | $1,960 | +3.09% | |
| 2025-03-03 | Sale | Colvin Richard A | Chief Medical Officer | 584 0.006% | $3.92 | $2,289 | +3.09% | |
| 2025-02-03 | Sale | Obenshain Andrew | President and CEO | 86 0.0008% | $7.39 | $636 | -41.96% | |
| 2025-02-03 | Sale | Klima Thomas J | See Remarks | 122 0.0012% | $7.39 | $902 | -41.96% | |
| 2025-02-03 | Sale | Colvin Richard A | Chief Medical Officer | 64 0.0006% | $7.39 | $473 | -41.96% | |
| 2025-02-03 | Sale | Vittiglio Joseph | Chief Business & Legal Officer | 238 0.0023% | $7.39 | $1,759 | -41.96% | |
| 2025-01-06 | Sale | Obenshain Andrew | President and CEO | 140 0.0013% | $9.24 | $1,294 | -56.25% | |
| 2025-01-06 | Sale | Colvin Richard A | Chief Medical Officer | 19 0.0002% | $9.24 | $176 | -56.25% | |
| 2024-12-10 | Sale | Obenshain Andrew | President and CEO | 971 0.0005% | $0.42 | $405 | -41.57% | |
| 2024-12-10 | Sale | Colvin Richard A | Chief Medical Officer | 2,824 0.0014% | $0.42 | $1,178 | -41.57% | |
| 2024-09-30 | Sale | Obenshain Andrew | President and CEO | 34,780 0.0189% | $0.53 | $18,270 | -30.22% | |
| 2024-09-30 | Sale | Klima Thomas J | See Remarks | 1,006 0.0005% | $0.53 | $529 | -30.22% | |
| 2024-06-03 | Sale | Klima Thomas J | See Remarks | 3,834 0.002% | $0.97 | $3,726 | -54.41% | |
| 2024-03-04 | Sale | Obenshain Andrew | President and CEO | 6,095 0.0031% | $1.53 | $9,311 | -60.83% | |
| 2024-03-04 | Sale | Klima Thomas J | See Remarks | 4,573 0.0023% | $1.53 | $6,986 | -60.83% | |
| 2024-03-01 | Sale | Colvin Richard A | Chief Medical Officer | 6,770 0.0034% | $1.53 | $10,342 | -60.16% | |
| 2024-02-05 | Sale | Obenshain Andrew | President and CEO | 1,879 0.0008% | $0.90 | $1,696 | -0.39% | |
| 2024-02-05 | Sale | Klima Thomas J | See Remarks | 2,714 0.0012% | $0.90 | $2,449 | -0.39% | |
| 2024-02-05 | Sale | Vittiglio Joseph | Chief Business & Legal Officer | 5,217 0.0023% | $0.90 | $4,708 | -0.39% |
Total: 512
*Gray background shows transactions not older than one year
Insider Historical Profitability
54.67%
| Obenshain Andrew | President and CEO | 18327 0.1872% | $60,662.37 | 0 | 22 | |
| Klima Thomas J | See Remarks | 7878 0.0805% | $26,076.18 | 0 | 9 | |
| Colvin Richard A | Chief Medical Officer | 7610 0.0777% | $25,189.10 | 0 | 9 | |
| Vittiglio Joseph | Chief Business & Legal Officer | 4501 0.046% | $14,898.31 | 0 | 2 | |
| TEPPER ROBERT I | 1215054 12.4111% | $4.02M | 0 | 9 | ||
| THIRD ROCK VENTURES LP | 10 percent owner | 1215054 12.4111% | $4.02M | 0 | 9 | |
| GILLIS STEVEN | director | 1041111 10.6344% | $3.45M | 0 | 7 | |
| Leschly Nick | director | 280149 2.8616% | $927,293.19 | 1 | 49 | <0.0001% |
| Cole Jason | Chief Strategy & Financial Off | 189546 1.9361% | $627,397.26 | 0 | 39 | |
| Whitten Jessica | Chief Accounting Officer | 49413 0.5047% | $163,557.03 | 0 | 3 | |
| Davidson David | Chief Medical Officer | 47787 0.4881% | $158,174.97 | 0 | 95 | |
| Gregory Philip D | Chief Scientific Officer | 46829 0.4783% | $155,003.99 | 0 | 56 | |
| Krawtschuk Christopher | Chief Financial Officer | 45474 0.4645% | $150,518.94 | 0 | 1 | |
| Eggimann Anne-Virginie | Chief Regulatory Officer | 42252 0.4316% | $139,854.12 | 0 | 1 | |
| Walsh Jeffrey T. | Chief Strategy Officer | 40921 0.418% | $135,448.51 | 0 | 57 | |
| Baird William D III | Chief Financial Officer | 35529 0.3629% | $117,600.99 | 0 | 4 | |
| FINGER ALISON CECILY | Chief Commercial Officer | 25103 0.2564% | $83,090.93 | 0 | 14 | |
| Smith-Farrell Joanne | COO, Oncology | 20609 0.2105% | $68,215.79 | 0 | 14 | |
| HIGH SUSANNA GATTI | Chief Operating Officer | 13750 0.1404% | $45,512.50 | 0 | 6 | |
| Leiderman Elisabeth | director | 11466 0.1171% | $37,952.46 | 0 | 1 | |
| WENTWORTH KORY JAMES | Principal Accounting Officer | 9512 0.0972% | $31,484.72 | 0 | 10 | |
| MARAGANORE JOHN | director | 5843 0.0597% | $19,340.33 | 2 | 4 | +99.03% |
| Sullivan Eric | Principal Accounting Officer | 5674 0.058% | $18,780.94 | 0 | 25 | |
| Burnett Katy | Principal Accounting Officer | 4097 0.0418% | $13,561.07 | 0 | 2 | |
| Schenkein David P | director | 3176 0.0324% | $10,512.56 | 1 | 2 | +30.47% |
| LYNCH DANIEL | director | 2800 0.0286% | $9,268.00 | 0 | 21 | |
| Mandell James | director | 1000 0.0102% | $3,310.00 | 0 | 8 | |
| Bain Linda | VP, Fin. & Business Operations | 0 0% | $0 | 0 | 8 | |
| Finer Mitchell H. | Chief Scientific Officer | 0 0% | $0 | 0 | 16 | |
| Vachon Mark | director | 0 0% | $0 | 0 | 5 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$155,580,641 | 77 | -24.21% | $27.72M | |
$53,490,060 | 55 | 19.35% | $28.82M | |
$36,557,692 | 17 | 3.38% | $35.52M | |
$17,594,514 | 16 | -20.37% | $28.91M | |
$1,044,754 | 13 | -23.07% | $39.45M | |
$19,300,035 | 11 | 45.88% | $30.68M | |
$232,423 | 8 | 14.22% | $37.65M | |
$22,090,972 | 7 | -3.49% | $38.58M | |
$1,446,995 | 5 | -3.03% | $30.24M | |
$149,996 | 5 | 16.26% | $36.34M | |
$26,254,149 | 5 | 49.97% | $36.32M | |
$147,504 | 5 | -36.70% | $29.09M | |
$25,999,992 | 4 | 13.36% | $29.76M | |
$657,791 | 4 | -52.05% | $33.13M | |
$5,045,759 | 4 | -11.33% | $26.97M | |
bluebird bio, Inc. (BLUE) | $1,801,761 | 4 | 54.67% | $32.41M |
$67,369,250 | 3 | -22.09% | $35.43M | |
$157,740 | 3 | 153.95% | $39M | |
$100,266 | 2 | 3.17% | $31.9M |
BLUE Institutional Investors: Active Positions
| Increased Positions | 34 | +19.54% | 350,758 | +11.31% |
| Decreased Positions | 76 | -43.68% | 640,382 | -20.65% |
| New Positions | 12 | New | 80,393 | New |
| Sold Out Positions | 47 | Sold Out | 372,067 | Sold Out |
| Total Postitions | 132 | -24.14% | 3M | -9.34% |
BLUE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $2,757.00 | 6.98% | 697,973 | -10,696 | -1.51% | 2025-03-31 |
| Vanguard Group Inc | $2,075.00 | 5.25% | 525,414 | +1,714 | +0.33% | 2024-12-31 |
| Geode Capital Management, Llc | $922.00 | 2.34% | 233,514 | -638 | -0.27% | 2024-12-31 |
| State Street Corp | $782.00 | 1.98% | 197,921 | +5,825 | +3.03% | 2024-12-31 |
| Ubs Group Ag | $420.00 | 1.06% | 106,302 | +101,347 | +2,045.35% | 2024-12-31 |
| National Bank Of Canada /Fi/ | $323.00 | 0.82% | 81,704 | +81,700 | +2.04M% | 2024-12-31 |
| Northern Trust Corp | $323.00 | 0.82% | 81,700 | +4,907 | +6.39% | 2024-12-31 |
| Avidity Partners Management Lp | $322.00 | 0.82% | 81,555 | -2 | <0.01% | 2024-12-31 |
| Lion Point Capital, Lp | $312.00 | 0.79% | 78,912 | <1 | <0.01% | 2024-12-31 |
| Pfm Health Sciences, Lp | $299.00 | 0.76% | 75,758 | +75,758 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.